The mechanism of action of (EI-S-(2-bromovinyll-2'-deoxyuridine (BVDUI was investigated using a 14C_ radiolabelled derivative. A remarkable accumulation of [14C]BVDU was detected in herpes simplex virus type 1 (HSV-11-infected cells, in greater quantities (la-foldl than in uninfected cells. Furthermore, selective incorporation of [l4C]BVDU was measured exclusively into HSV-1 DNA. Further studies on the cellular kinetic and metabolic fate of BVDU indicated that in HSV-1-infected cells it was phosphorylated intracellularly to its mono-(BVDU-MPI and triphosphate (BVDU-TPI derivatives. The amount of BVDU-MP was 10 times higher than BVDU-TP. BVDU entered infected cells very quickly and was rapidly converted into BVDU-MP which, in turn, was further metabolized to BVDU-TP. After 5 h incubation, 13% of initial radioactivity was found in the SDS phase, representing mainly DNA and proteins, of HSV-1-infected cells and only 2% in uninfected cells, further confirming the selective incorporation of the compound into viral DNA. Following removal of BVDU from culture medium, the cellular decay of BVDU-phosphorylated derivatives was rather slow, with an estimated half-life of 10 h, and their disappearance from the cytosol was paralleled by a progressive accumulation of radioactivity in the SDS phase. These results give direct evidence for the selective cellular uptake, metabolism and viral DNA accumulation of BVDU in HSV-1-infected cells, representing the major factors for its powerful and specific anti-herpesvirus activity.
Introduction
The selectivity of several nucleoside analogues as antiherpesvirus agents is due to their preferential intracellular phosphorylation by the virus-encoded thymidine kinase (TK) (De Clercq, 1993) . Indeed, the TK encoded by the herpes simplex virus (HSV) and varicella zoster virus (VZV) genomes has a broad substrate specificity and, I unlike cellular TK, may recognize and eventually phosphorylate these nucleosides (De Clercq, 1984 , 1993 . Among nucleoside derivatives, (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU) has proved to be one of the most potent and selective inhibitors of HSV-1 and.YZV (De Clercq et al., 1979 , 1980a ,b, 1982 De Clercq, 1982 , 1986 Allaudeen et al., 1981) due to its exceptionally high affinity for viral TKs (Allaudeen et al., 1982; Ayisi et al., 1984; De Clercq et al., 1985a; Yokota et al., 1987; Balzarini &De Clercq, 1989; Spadari et al., 1995) . Owing to its lower affinity for other cellular and viral TKs, BVDU exhibits low cytotoxicity and poor inhibitory activity against viral infection induced by HSV-2 and by HSV-1 strains lacking TK (HSV-1 TK-) (Cheng et al., 1981; Cheng, 1984; De Clercq et al., 1985b) . BVDU is converted intracellularly by viral TK into BVDU monophosphate (BVDU-MP), then BVDU diphosphate (BVDU-DP) and finally (through cellular nucleotide diphosphate kinase) into BVDU triphosphate (BVDU-TP) (Ayisi et al., 1984) . It has been proposed that the antiviral action ofBVDU may be mainly based upon the incorporation of BVDU-TP into viral DNA, which would render the DNA more prone to degradation as well as less functional for transcription (Mancini et al., 1983) . However, evidence for a selective uptake and cellular accumulation ofBVDU in HSV-1-infected cells has been gathered in studies that, for assay detection limits, were carried out at BVDU concentrations well above its IC so on HSV replication. Further, only indirect proof for BVDU incorporation, by viral DNA polymerase, into herpesvirus DNA was obtained by competition experiments with radiolabelled thymidine (Allaudeen et al., 1982) . The aim of the present study was to investigate directly, at pharmacologically relevant doses, the uptake and cellular accumulation in HSV- for 24 h, the monolayer cell cultures were washed with PBS and treated at 3TC for 1 h with 300 mM of lysis buffer containing 0.2% SDS, 1 mM EDTA, 0.1 M NaCl, 10 mM Tris-HCl pH 7.4,0.5% N-laurylsarcosylate and 0.2 mg Pronase (Calbiochem-Bering). The lysates were layered onto 8 mL of CsCl solution (1.71 g mL-l) in distilled water and centrifuged far 103 h at 23000 r.p.m. with a SW41Ti rotor (Beckman). The fractions were collected from the bottom of the tubes, and 70 ul, of each fraction were spotted on Whatman GF/C filters, which were washed twice with 5% TCA for 20 min; their radioactivity was determined in a liquid scintillation counter. The density of each fraction was calculated from the refraction index measured with a refractometer. 
Cells and virus
Vero (Green monkey kidney) cells were grown in MEM (Gibco BRL) supplemented with 10% fetal calf serum (Gibco BRL) and 2 mM L-glutamine (Gibco BRL). HSV-l (strain HF) and HSV-2 (strain G) were obtained from the ATCC. HSV-l TK-(strain B2006) was obtained from E De Clercq (Rega Institute, Leuven, Belgium).
Cellular drug uptake
Confluent Verocells(in 60 mm Petri dishes) were infected with HSV-l or HSV-2 or HSV TK-at an m.o.i. of 10 p.f.u. cell-l. Each infection was performed in duplicate.
After 1 h adsorption at 3TC, the viral inoculum was removed and the cells were washed with PBS.
[l4C]BVDU was added at a final concentration of 0.5 f.!M. BVDU concentration was selected on the basis of preliminary experiments designed to determine the concentration inhibiting HSV-l replication by >90%. The cellswere harvested at six time intervals (0.5, 1, 2, 5, 8 and 20 h), washed in PBS and then their radioactivity was measured in a liquid scintillation counter.
Materials and Experimental Procedures
Caesium chloride equilibrium gradient analysis Vero cells (in 60 mm Petri dishes) at 80-90% confluency were mock-infected or infected with HSV-l, HSV-2 or HSV-l TK-at an m.o.i. of 10 p.f.u. cell-l. After 1 h adsorption at 37°C, the viral inoculum was removed, the
]uridine (sp, act. 12 mCi mmol'") was synthesized by Amersham International (Amersham, UK). BVDU and its phosphorylated derivatives, BVDU-MP, BVDU-DP and BVDU-TP were synthesized in the Department of Chemistry of Berlin Chemie (Berlin, Germany) by H Freude.
gain further insight on the drug selectivityand on the role played by TK in these processes, these studies were also performed in mock-infected cellsand in cellsinfected with HSV-2 or HSV-l TK-. Furthermore, the kinetics of formation and stability ofBVDU phosphorylated metabolites were investigated in mock-and HSV-l-infected cells exposed to [l4C]BVDU (at a clinically achievable plasma concentration) for a prolonged (up to 24 h) or pulsed (2 h) period. Radioactive BVDU, its phosphorylated derivatives and its major degradation metabolite (E)-5-(2-bromovinyl)-uracil (BVU) were analysed by reverse-phase (RP) HPLC in the extracellularmedium and in the cellular compartments. Fraction number
Analysis of mono-, di-and triphosphate metabolites of f 4 Cj BVDU in medium and ethanol phase of HSV-1-infected cells Monophosphate ([l4C]BVDU-MP), diphosphate ([14C]
Cellular extracts following pulse treatment with [14CjBVDU Cell cultures, infection and incubation modalities were as described in the preceding paragraph.
[14C]BVDU (5 11M) was added to the incubation medium and left in contact with cells for 2 h. The radioactive BVDU was then removed from the extracellular medium and replaced with drug-free medium after washing the cells with PBS (time zero). Incubation of cells was continued for various lengths of time (0.5, 1, 2, 6, 24 h). Total radioactivity, BVDU and its metabolites were determined in the extracellular and cellular compartments as described above. The half-lives of BVDU phosphates were estimated by log-linear regression of counts (d.p.m.) versus time. tuted mainly of cell cytosol, whereas the SDS phase is composed of ethanol non-soluble fraction (proteins) and 128000 DNA. Mock-infected cells were processed as described above. In HSV-1-infected cells, radioactivity rose rapidly, reaching a peak at 8 h, and remaining stable up to 20 h (Fig. 1) . By contrast, in both HSV-1 TK-and mockinfected cells the uptake of radioactivity was negligible at BVDU-DP), triphosphate ([14C]BVDU-TP) and BVU metabolites were extracted from culture medium and cytosol by a liquid-liquid extraction procedure before chromatographic analysis, Each sample (3 mL) was centrifuged at 3000 g for 15 min at 4°C after the addition of 6 mL of a mixture of ethanol-saline buffer (1:1; v/v). The supernatant was removed and rota-evaporated to dryness under vacuum at 40°C. The residue was redissolved in 150 f..tL of mobile phase. 50 f..tL of the redissolved residue was subjected to RP-HPLC.
The RP-HPLC system consisted of a gradient solvent delivery pump, model 125 (Beckman), equipped with an automatic sample injector model 232 (Gilson), a Supelco column ABZ, 125x4.6 mm i.d. and 5 urn spheric particle size, a UV detector (Beckman, model 168), a radiodetector (EG&G Berthold, model 507 B) and an Epson AX 400 2 computer with System Gold software (Beckman). The HPLC system was operated with a step gradient at room temperature with a flow rate of 1 mL min-I. The wavelength of the UV detector was 254 nm.
The mobile phase consisted of 0.1 M PBS pH 6.1 (solvent A) and acetonitrile (solvent B). The compounds were eluted from the column by a three-step gradient. In the first step solvent B was 3.5% after 12 min of the injection (second step), the percentage of solvent B was increased to 11% in 5 min, then after elution of BVDU (28 minutes), solvent B was decreased to 3.5% in 5 min. The column was calibrated for the retention times of synthetic BVDU-TP, BVDU-DP, BVDU-MP, BVU and BVDU (5, 7, 11,23 and 28 min). all time-points considered. The amount of radioactivity in HSY-1-infected cells, at 8 h, was 18 times greater than in mock-infected cells. In HSY-2-infected cells a minor peak of cellular accumulation (corresponding to about eightfold more than that measured in mock-infected cells) was observed at 8 h (Fig. 1) . Given the size of the cell volume, in HSY-1-and HSY-2-infected cells the intracellular drug concentration (at 8 h) could be estimated as 43 [.tM and 7.5 f!M (corresponding about to 85-and 15-fold more than the initial concentration in the extracellular medium), respectively.
Incorporation of [14CjBVDU into viral DNA
HSY-and mock-infected Vero cells were incubated with 0.5 I-lM [14C]BVDU for 24 h. The viral and cellular DNA were separated by isopycnic centrifugation in a CsCI gradient. Under our experimental conditions [14C]thymidine was incorporated into viral and cellular DNA (data not shown), while [14C]BVDU was incorporated exclusively into HSY-1 DNA (Fig. 2a) . No radioactive BVDU could be detected in HSY-l TK-or in mock infected cells (Fig. 2b,d) . Also, no evidence for [14C]BVDU incorporation into viral DNA was obtained when Yero cells were infected with HSY-2 (Fig. 2c) . DNA-DNA hybridization with HSY probe confirmed that the DNA with a buoyant density of 1.72 (Fig. 2a) corresponded exactly to HSY-l viral DNA (data not shown).
Detection of [14CjBVDU and its phosphate metabolites following prolonged exposure
These experiments were carried out to evaluate the kinetics of formation of BYDU metabolites during a continuous exposure of the infected cells to [l4C]BVDU (5 I-lM).
Ethanolphase. In this compartment the total radioactivity rose rapidly during the first 20 min of incubation (Fig.  3a) . At the peak (20-30 min), approximately 35% of the radioactivity initially present in the extracellular medium was contained in the ethanol phase (cytosol); total radioactivity sharply decreased after 30 min, remaining fairly constant up to 5-8 h and then declined until the end of incubation (24 h) (Fig. 3a) .
Most (80%) of the radioactivity present in the cytosol was identified as BVDU-MP, while BVDU-TP and the parent compound, BVDU, each represented about 10% of the total (Fig. 3b) . The relative ratio BVDU-MP:BVDU-TP (around 10:1 in favour of the monophosphate), remained constant during the first 8 h of treatment and then decreased to 4:1 (at 24 h).
A small amount ofBVU was also detected, although it appeared only after 8 h of incubation (Fig. 3b) . In mockinfected cells, apart from BVDU, only its metabolite BVU was measured (data not shown).
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Anti·HSV·l activity of [l4C]BVDU SDS phase. Total radioactivity in this compartment (protein and DNA) of HSY-1-infected cells rose steadily with .ti~e, reaching a peak after 5. h of incubation, jlnd remaming constant up to 24 h (FIg. 4) . Approximately 11-13% of the initial radioactivity was incorporated in this compartment of infected cells,while only 2% of radioactivity was incorporated in the same compartment of mockinfected cells. Since [14C]BVDU is selectively incorporated into viral DNA (see above), it is conceivable that at least 9-11% of the radioactivity found in infected cells may be attributed to BVDU incorporated into viral DNA.
Detection of phosphate derivatives of BVDU in HSV-1-infected cells after pulse treatment with [14CjBVDU
To assess the kinetics of cellular phosphate metabolites of BVDU, a further set of experiments was performed in which cells were infected for 20 h with HSY-l at low m.o.i, (0.01 p.f.u. cell-I) and exposed to a pulse (2 h) treatment with 5 I-lM [14C]BVDU followed by drug-free incubation up to 24 h. At selected times, total radioactivity, BVDU and its metabolites were measured in the extracellular medium and in cellular compartments (Fig. 5) .
Extracellular medium. Immediately upon reincubation of cells,there was an immediate efflux ofradioactivity followed by a steady decline. Analysis of the effluent revealed that most of the radioactivity could be attributed to BVU, the inactive metabolite ofBVDU (data not shown).
Ethanolphase. In this compartment most of the radioactivity present could be identified as BVDU-MP (Fig. 5a ). BVDU-TP was present in a smaller proportion relative to BVDU-MP (1:6) (Fig. 5b) . Following a rapid decrease in the first 60 min, BVDU-MP and BVDU-TP declined at a very slow rate until 24 h. The kinetics of both compounds corresponded to half-lives of approximately 10 h.
SDS phase.
The radioactivity present in the SDS phase (thus mainly related to drug incorporated into viral DNA, see above) consistently increased throughout the reincubation period (Fig. 5c ).
Discussion
The investigations summarized in this paper further define the mechanisms through which BVDU inhibits viral DNA synthesis and highlight the temporal sequence for the intracellular formation of BVDU phosphorylated derivatives.
Several reports point to the relationship between the incorporation of nucleoside analogues into viral DNA and a reduction of virus infectivity and DNA integrity. In the present study, we have demonstrated directly, using [14C]BVDU, that, under our experimental conditions, this compound is incorporated exclusively into viral DNA at concentrations that yield effective inhibition of HSV-l replication in cultured Vero cells. Unlike [14C]thymidine, no incorporation of [14C]BVDU in cellular DNA was observed, suggesting that the antiviral activity ofBVDU is probably the result of a selective incorporation into HSV-1 DNA. Also, no incorporation into viral DNA was detected in HSV-2-or HSV-l 'I'Kt-infected cells. At the same time, we have demonstrated that [14C]BVDU is selectively taken up by HSV-l-infected cells, but not to an appreciable extent by mock-or HSV-l T'K'-infected cells. A small quantity of [14C]BVDU was also detected in cells infected by HSV-2. Of interest is the large difference in the total accumulation of [14C]BVDU between HSV-land HSV-2-infected cells.The radioactivity found only in HSV-2-and HSV-l-infected cells is the result of different viral metabolism of BVDU, which is directly correlated with preferential phosphorylation by specific viral TK. The total radioactivity found in HSV-2-infected cells represents mainly BVDU-MP (Ayisi et af., 1984 (Ayisi et af., , 1987 , while in HSV-l-infected cells it is the sum of BVDU-MP, BVDU-Tp, BVU and BVDU.
In this study we have also gathered direct evidence of the cellular kinetic and metabolic fate ofBVDU following its incorporation in HSV-l-infected cells.The experimental conditions for these 'in vitro' investigations were chosen to be as relevant as possible to the pathological and therapeutic situation. Thus, the viral load (0.01 p.f.u. cell-1) was purposely low in order to obtain, as in the natural infection, heterogeneity in the viral replication stages in the cell population. BVDU was also added late post-infection (20 h) in order to ensure adequate expression of viral TK in infected cells; in addition the BVDU concentration utilized (5 I-tM) was similar to the steady state plasma level achieved at peak after repeated oral administrations of 125 mg BVDU to humans. Several interesting findings need to be discussed. First, the massive transfer of radioactivity from the extracellular to the intracellular compartments in infected cells is remarkable for the extent (approximately 35% of initial radioactivity moved intracellu1arly) and the rapidity (20 to 30 min) with which it occurs. A second important finding concerns the metabolism of BVDU once it enters the infected cell. The results showing the early rapid rise of BVDU-MP in the cytosol (ethanol phase) clearly indicate that phosphorylation by the viral TK occurs rapidly and with great efficiency. This is in keeping with the affinity of BVDU for viral HSV-l TK, which is one of the highest among nucleoside analogues (Vere Hodge & Perkins, 1989; Descamps & De Clercq, 1981) . Among the phosphorylated derivatives of BVDU, the only one detected in appreciable amounts, besides BVDU-MP, was BVDU-TP, which was present in a ratio 570 1:10 relative to BVDU-MP and followed a similar time course as the latter: early rise (20-30 min) followed by steady decline throughout the incubation period (24 h). BVDU-DP was not detected in the present experimental conditions; this might be a consequence of its rapid conversion to BVDU-TP and/or to a slow interconversion from BVDU-MP, which is the rgte-limiting step of this biochemical pathway. Third, the half-life of BVDU-TP was 10 h, which is longer than that of acyclovir triphosphate (0.7 h) (Vere Hodge & Perkins, 1989) . The high entrapment of BVDU phosphate suggests that BVDU may inhibit viral replication much more effectively than acyclovir when treatment times are reduced (Iafrate et al., 1997) . A fourth major finding is the radioactivity in the DNA and protein compartment (SDS phase): in HSV-linfected cells the radioactivity corresponds to about fourto fivefold the amount in mock-infected cells. The low radioactivity in mock-infected cells most probably represents aspecific binding to cellular protein. The difference in radioactivity in this phase between HSV-l and mockinfected cells might represent the real incorporation into viral DNA, which ensues after 2 h of incubation, reaches a peak at 5 h and then plateaus. This time-dependent pattern of nuclear incorporation correlates with the decrease in radioactivity, attributable to BVDU phosphorylated derivatives, found in the cytosol. This time course is also exactly superimposable on the time response of cellular uptake.
Thus, these data indicate that BVDU enters infected cells at a very fast rate, is rapidly and almost stoichiometrically converted into BVDU-MP, which in turn is further metabolized to BVDU-TP. As the concentration of this latter derivative rises in the cytosol, it appears to be immediately incorporated into viral DNA.
In conclusion, the selectivity of BVDU as an antiherpesvirus agent primarily depends on a specific phosphorylation by the viral TK, whereas its antiviral action seems to be related to its incorporation into viral DNA.
